Free Oncology CME

  • FREE

    Prediction and management of bone complications in prostate cancer

    Each year, over 268,000 cases of prostate cancer are diagnosed. Although early prostate cancer may be cured with surgery or radiation therapy, more than 50% of men will experience recurrence after definitive treatment. New treatment options for advanced prostate cancer have further improved survival and increased the number of patients living with castration-resistant prostate cancer (CRPC). But despite the established improvements in survival, a cornerstone of treatment, androgen deprivation therapy (ADT), has been associated with well-characterized negative effects on bone health like skeletal-related events (SREs) and bone metastases. These complications the primary drivers of morbidity and mortality among people with CRPC. Maintaining bone health in patients with CRPC requires routine monitoring and proactive management. Bone mineral density (BMD) loss places men with CRPC at elevated risk for osteoporosis and future fractures.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 11/29/2022
    • Expiration of CME credit: 11/29/2024
  • FREE

    Myeloma bone disease: Monitoring and management

    In this online, self-learning activity:

    Multiple myeloma (MM) is the most common hematologic malignancy after non-Hodgkin lymphoma, with an incidence of over 34,000 and an annual mortality rate of over 12,000. MM-induced osteocyte apoptosis facilitates MM cell survival, and patients with MM are at high risk for bone disease. Osteolytic lesions are reported in up to four out of five newly diagnosed with MM, and throughout their disease course, up to 90% of patients will eventually develop bone lesions. The presence of bone lesions increases MM patient risk for skeletal-related events (SREs), such as fractures, spinal cord compression, or need for surgery or radiotherapy. Bone disease and SREs can have serious consequences in MM, leading to worsened quality-of-life and prospects for survival. Patients who experience fracture after MM diagnosis have a two-fold increased risk of death relative to those who do not experience fracture. Yet bone disease frequently goes untreated in patients with MM, suggesting that clinicians are not familiar with the serious effects of MM.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Expiration of CME credit: 12/21/2024
  • FREE

    Therapeutic options and present gaps in the management of refractory and metastatic differentiated thyroid cancer

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: May 11, 2023
    • Expiration of CME credit: May 11, 2024
  • FREE

    Initial and later line approaches to the systemic treatment of unresectable and metastatic gastric and gastroesophageal junction (GEJ) cancer

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Staging of GC & GEJC depends on the tumor’s histopathology, location, and degree of spread, and 36% of patients in the U.S. are diagnosed in the advanced stages of the disease because the signs and symptoms are often initially clinically silent for most of the disease course, and missed opportunities for identification are not uncommon. The prognosis of GC & GEJC is poor: the 5-year overall survival (OS) rate of GC is 32%, with the five-year OS rate of patients with advanced disease is six percent.

    Target Audience:

    HCPs including: Medical oncologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 02/01/2023
    • Expiration of CME credit: 02/01/2024
  • FREE

    Top strategies in the management of advanced renal cell carcinoma (RCC)

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in 79,000 people and account for close to 14,000 deaths in the U.S. per year. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 14%, representing an area of ongoing clinical need. Treatment selection in advanced, clear cell RCC treatment depends on prognostic scoring and may include mono- or combination therapy with immunotherapy and an antiangiogenic agent, and many of the same agents are used to treat advanced, non-clear cell RCC.

    Target Audience:

    HCPs including: Medical oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 02/22/2023
    • Expiration of CME credit: 02/22/2024
  • FREE

    The next frontier in myelofibrosis management

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Myelofibrosis (MF) is a hematologic malignancy characterized by fibrosis buildup in the bone marrow, inadequate hematopoiesis, and splenomegaly. MF is a rare form of cancer, with an incidence of about 0.4 per 100,000 person-years in the United States. MF is the most aggressive form of the Philadelphia-negative, BCR-ABL1 chronic myeloproliferative neoplasms, with a five-year mortality rate of 51%. In patients with other comorbidities at the time of or after diagnosis, such as diabetes, hypertension, pulmonary diseases, or obesity, even greater reductions in lifespan can be expected. It has a considerable effect on patient quality of life and is associated not only with feelings of fear, anger, and grief common of an oncologic diagnosis, but also a gradual loss of ability to perform activities of daily living and hobbies. MF imposes a significant financial burden through direct and indirect costs, and patients who are diagnosed at a younger age often become unemployed as the disease progresses.

    Target Audience:

    The following HCPs: hematologists and oncologists in the community and academic settings; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with MF.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 03/08/2023
    • Expiration of CME credit: 03/08/2024
  • FREE

    Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Graft-versus-host disease (GvHD) is an immune-mediated response that occurs in recipients of allogenic hematopoietic cell transplantation (HCT). GvHD can be further categorized into acute and chronic cases. Maculopapular rash, follicular erythema, epidermolysis, are common manifestations of acute GvHD, in addition to liver and gastrointestinal dysfunction such as hyperbilirubinemia, nausea, and diarrhea. This activity focuses on chronic GvHD, which has more extensive multi-organ involvement including the liver, eyes, mouth, lungs, skin, genitalia, and gastrointestinal tract.

    Target Audience:

    The following HCPs: hematologists and oncologists; nurse practitioners, physician assistants, and pharmacists who specialize in oncology; and those who otherwise commonly care for or clinically encounter patients with GVHD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 03/31/2023
    • Expiration of CME credit: 03/31/2025
  • FREE

    Best practices in the real-world clinical management of malignant mesothelioma

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Malignant mesothelioma (MM) is a relatively rare, aggressive cancer that most commonly affects the pleural space (81%) in cases of malignant pleural mesothelioma (MPM), followed by the peritoneum (9%). Over 80% of MPM patients and 33% of patients with peritoneal MM have a documented prior exposure to asbestos or related minerals. It is thought that the inhaled asbestos fibers interact with mesothelial and inflammatory cells, leading to repeatedly prolonged cell cycles and direct DNA damage. There are three distinct histologic subtypes of MPM, but determining subtypes requires expert assessment and suitable biopsies that are not always available, which may lead to delays in the start of treatment.

    Target Audience:

    HCPs including: Medical oncologists and pulmonologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with malignant mesothelioma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 05/04/2023
    • Expiration of CME credit: 05/04/2024